{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:28:13Z","timestamp":1787164093939,"version":"build-2736575974"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This phase II, open-label, prospective, multicenter study evaluated the efficacy and safety of intermittent intravenous doxercalciferol in treating secondary hyperparathyroidism (SHPT) in Chinese maintenance hemodialysis (MHD) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MHD patients aged 18 to 75 years with a serum intact parathyroid hormone (iPTH) level of 400\u00a0pg\/mL or higher were enrolled and stratified into Mild, Moderate, and Severe groups based on baseline iPTH levels (400\u2013599.99, 600\u2013799.99, and \u2265800\u00a0pg\/mL, respectively). Patients received an initial dose of 4\u00a0\u03bcg of doxercalciferol three times weekly for 12 weeks, with subsequent dose adjustments to target iPTH levels of 150\u2013300\u00a0pg\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 45 patients enrolled, 44 completed the study, with 20 patients in the Mild Group, 12 in the Moderate Group, and 12 in the Severe Group. The baseline iPTH level for the 44 patients was 655.05 (469.68, 831.40) pg\/mL, which decreased to 269.90 (176.45, 365.65) pg\/mL after 12 weeks of treatment. The overall mean percentage change in iPTH levels from baseline to week 12 was \u221255.45% \u00b1 20.08%, with 86.4% of patients (38 cases) achieving a \u226530% reduction compared to baseline. At week 12, 80.00% of patients (16 cases) in the Mild Group had iPTH levels within the target range of 150\u2013300\u00a0pg\/mL or less than 150\u00a0pg\/mL, compared to 41.76% (5 cases) in the Moderate Group and 33.33% (4 cases) in the Severe Group. All three groups showed a decrease in serum alkaline phosphatase (ALP) levels, with the Severe Group experiencing a statistically significant reduction (P = 0.001). The most common adverse event was hypercalcemia, occurring in 33.3% of patients (15 cases), with only 8.9% (4 cases) experiencing severe hypercalcemia (serum calcium &amp;gt;2.8\u00a0mmol\/L). Hypercalcemia was resolved after dose reduction or discontinuation of the medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Intermittent intravenous doxercalciferol effectively reduces iPTH levels in Chinese MHD patients, with a manageable safety profile. While hypercalcemia is a concern, the incidence of severe cases is not high. This study supports doxercalciferol as a potential treatment option for SHPT in Chinese MHD patients.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Clinical Trial Registration:<\/jats:bold>\n                      <jats:ext-link>https:\/\/www.chictr.org.cn\/showproj.html?proj=187332<\/jats:ext-link>\n                      , identifier ChiCTR2300073196.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1574679","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:10:32Z","timestamp":1744330232000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of intermittent intravenous doxercalciferol in the treatment of secondary hyperparathyroidism in Chinese patients on maintenance hemodialysis: a phase II, open-label, prospective, multicenter study"],"prefix":"10.3389","volume":"16","author":[{"given":"Guang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangbao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1046\/j.1523-1755.63.s85.12.x","article-title":"Use of active vitamin D sterols in patients with chronic kidney disease, stages 3 and 4. Kidney","volume":"85","author":"Coburn","year":"2003","journal-title":"Int. Suppl"},{"key":"B2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.5414\/cnp70319","article-title":"Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol - a dose equivalency and titration study","volume":"70","author":"Fadem","year":"2008","journal-title":"Clin. Nephrol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.2215\/CJN.01040308","article-title":"Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results","volume":"3","author":"Fishbane","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/ajkd.2000.16193","article-title":"Intermittent doxercalciferol (1\u03b1-Hydroxyvitamin D2) therapy for secondary hyperparathyroidism","volume":"36","author":"Fraz\u00e3o","year":"2000","journal-title":"Am. J. Kidney Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1744-9987.12058","article-title":"Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder","volume":"17","author":"Fukagawa","year":"2013","journal-title":"Ther. Apher. Dialysis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/medicina57020186","article-title":"Vitamin D and glomerulonephritis","volume":"57","author":"Gembillo","year":"2021","journal-title":"Med. Kaunas."},{"key":"B7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"109437","DOI":"10.1016\/j.steroids.2024.109437","article-title":"Significance of vitamin D responsiveness on the etiology of vitamin D-related diseases","volume":"207","author":"J\u00e4rvelin","year":"2024","journal-title":"Steroids"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/ndt\/gfac236","article-title":"Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s","volume":"38","author":"Ketteler","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"B10","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/s0272-6386(01)80010-x","article-title":"Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1\u03b1-hydroxyvitamin D2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison","volume":"37","author":"Maung","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2003.08.009","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5551\/jat.RV22012","article-title":"Phosphate and coronary artery disease in patients with chronic kidney disease","volume":"31","author":"Ogata","year":"2024","journal-title":"J. Atheroscler. Thrombosis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.5414\/cnp59471","article-title":"Effect of doxercalciferol (1alpha-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy","volume":"59","author":"Parisi","year":"2003","journal-title":"Clin. Nephrol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nefroe.2022.11.014","article-title":"Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet","volume":"43","author":"Pereira","year":"2023","journal-title":"Nefrol. Engl. Ed."},{"key":"B15","doi-asserted-by":"publisher","first-page":"6934706","DOI":"10.1155\/2017\/6934706","article-title":"Impact of different levels of iPTH on all-cause mortality in dialysis patients with secondary hyperparathyroidism after parathyroidectomy","volume":"2017","author":"Qiu","year":"2017","journal-title":"BioMed Res. Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1210\/endrev\/bnac031","article-title":"Bone turnover markers: basic biology to clinical applications","volume":"44","author":"Schini","year":"2023","journal-title":"Endocr. Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/ki.1997.39","article-title":"Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism","volume":"51","author":"Tan","year":"1997","journal-title":"Kidney Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2215\/CJN.07960719","article-title":"Conversion from intravenous vitamin D analogs to oral calcitriol in patients receiving maintenance hemodialysis","volume":"15","author":"Thadhani","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamainternmed.2022.6817","article-title":"Prevalence of chronic kidney disease in China: results from the sixth China chronic disease and risk factor surveillance","volume":"183","author":"Wang","year":"2023","journal-title":"JAMA Intern. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1400891","DOI":"10.3389\/fendo.2024.1400891","article-title":"Estimating the global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/ki.2010.352","article-title":"Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism","volume":"79","author":"Wesseling-Perry","year":"2011","journal-title":"Kidney Int."},{"key":"B22","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/1744-9987.14177","article-title":"Current therapeutic approach of chronic kidney disease-mineral and bone disorder","volume":"28","author":"Zaimi","year":"2024","journal-title":"Ther. Apher. Dialysis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1159\/000089707","article-title":"Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol","volume":"25","author":"Zisman","year":"2005","journal-title":"Am. J. Nephrol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1574679\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:10:33Z","timestamp":1744330233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1574679\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":24,"alternative-id":["10.3389\/fphar.2025.1574679"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1574679","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"article-number":"1574679"}}